CareDx Appoints Jing Huang Chief Data and AI Officer — read more: https://lnkd.in/gMzwmMW5
CareDx, Inc.
生物技术研究
Brisbane，California 19,316 位关注者
Dedicated to transplant patients. Leading with innovation.
关于我们
CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions. NASDAQ:CDNA About AlloSure? AlloSure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. AlloSure is a clinical-grade, proprietary Next-Generation Sequencing (NGS) based test to detect donor-derived cell-free DNA (dd-cfDNA) in order to identify organ injury in kidney transplant recipients. AlloSure is analytically validated as a sensitive, specific, and precise measurement of dd-cfDNA. AlloSure detects active rejection (acute active ABMR, chronic active ABMR, or TCMR) with high accuracy, outperforms serum creatinine in kidney transplant recipients, and is highly sensitive in distinguishing ABMR from no ABMR. AlloSure is performed in the CareDx CLIA-certified laboratory. https://www.allosure.com/ About AlloMap? AlloMap Molecular Expression Testing is a non-invasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the CareDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients. https://www.allomap.com/
- 网站
-
https://www.caredx.com
CareDx, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 501-1,000 人
- 总部
- Brisbane，California
- 类型
- 上市公司
- 领域
- Diagnostics和Transplant Patient Care
地点
-
主要
获取路线
8000 Marina Blvd
US，California，Brisbane，94005
CareDx, Inc.员工
动态
-
CareDx is heading to Istanbul! Join us at the 30th International Congress of The Transplantation Society (TTS 2024) from September 22-25, 2024. Swing by Booth 17 to discover our latest innovations in transplant products and solutions. We’re excited to connect, share insights and explore new opportunities with you. Don’t miss out—come say hello! See you there! #CareDx #TTS2024 #TransplantInnovation #HealthcareEvents
-
-
CareDx Appoints Keith Kennedy Chief Operating Officer and Jessica Meng Chief Commercial Officer—read more: https://bit.ly/3B0HTFo
-
-
CareDx is proud to have sponsored last week's 2024 Transplant Games in Birmingham, Alabama. This incredible event unites the largest gathering of organ transplant recipients, caregivers, living donors, donor families, and the transplant community, showcasing the transformative and life-saving power of organ donation and transplantation. Learn more about Scott, a heart transplant recipient and future Games participant, in this story by reporter Scott Minshall with CBS 42. #TransplantGames2024 #CareDx #OrganDonation #Transplantation
-
CareDx, Inc.转发了
On June 14, we presented Dr. Robert A. Montgomery with the ACS Jacobson Innovation Award, recognizing his groundbreaking contributions to transplantation surgery. Dr. Montgomery is a distinguished transplant surgeon renowned for pioneering "domino" paired kidney donations and leading the world’s first successful pig-to-human kidney xenotransplant at NYU Langone Health NYU Grossman School of Medicine. He is the 30th recipient of the award, joining a list of surgeon innovators who have revolutionized the field of surgery and saved countless lives. Learn more about the Jacobson Award, Dr. Montgomery's career, and his personal journey: https://lnkd.in/gbNawCV8
-
-
Congratulations to Dr. Alexandre Loupy, the Paris Institute for Transplantation and Organ Regeneration, along with researchers in the U.S. and Belgium for their landmark study published in Nature Medicine! #2024ATCPhilly #transplant #kidneytransplant
PUPH @Necker Hospital, Head of INSERM unit Paris Translational Research Center for Organ Transplantation ?? Adjunct Professor Transplant Department @Cedars Sinai L.A USA.
Fresh from the American Transplant Congress (ATC) in Philadelphia We are thrilled to announce a transformative leap in kidney transplant care with our new study just released in Nature Medicine Nature Portfolio. Discover donor-derived cell-free DNA (dd-cfDNA) ??, a non-invasive liquid biopsy method that redefines rejection detection and minimize the need for invasive graft biopsies. Key Milestones: ?? Global Collaboration: ?? International consortium of 14 centers across Europe and the US led by our institute #PITOR ???? ???? . ?? Extensive Study: ?? Encompassing 2,882 kidney transplant recipients, including both adults and pediatric patients. ?? Precision Detection: ?? dd-cfDNA levels precisely correlate with various types of transplant rejection, highlighting its potential to monitor and improve treatment efficacy. ?? Enhanced Accuracy: ?? Integrating routine transplant monitoring with dd-cfDNA significantly increase rejection detection accuracy, showcasing its crucial role alongside standard care. ?? Cost Efficiency: ?? This innovative approach simplifies the care pathway, reducing unnecessary biopsies and lowering healthcare costs. ?? Proactive Intervention: ? Early detection of clinical and subclinical rejection paves the way for more effective and timely interventions. Kudos to the amazing Nature editorial board who helped us to further improve the paper Anna Maria Ranzoni Joao Monteiro Eric Vibert, MD, PhD Agnès Audier Franck Mouthon Alex Zhavoronkov Didier Samuel Antoine Tesniere Matthieu Resche-Rigon Edouard Kaminski AP-HP, Assistance Publique - H?pitaux de Paris Andreas Linkermann Lise ALTER Matthieu Landon Bruno Bonnell Marine Jeantet Michel Tsimaratos AGENCE DE LA BIOMEDECINE Renaloo : la voix des malades du rein. SFT - Société Francophone de Transplantation SFNDT - Société Francophone de Néphrologie, Dialyse et Transplantation ESOT - European Society for Organ Transplantation Didier Frandji Carmen Lefaucheur OrganX Foundation Catherine Chaussain Didier Letourneur Alexandre Mebazaa Hélène Cart-Grandjean Eric Labaye
-
-
Starting Shortly! Don't miss out! Our symposium at ATC 2024, "From Invasive to Intelligent: Utilizing Cutting-Edge Artificial Intelligence and Molecular Diagnostics in Real-World Clinical Practice," is about to begin! ?? Today ? 12:15 PM - 1:15 PM EDT ?? Live on Zoom Join us as we explore the innovative intersections of AI and molecular diagnostics in clinical settings. Catch it live or on-demand at your convenience! ?? Tune in here: https://lnkd.in/gFsF6MNR
-
-
Explore the future of chimerism analysis with next-generation sequencing using AlloSeq HCT! Join our webinar on April 30th for exclusive insights into the latest advancements. Register now! #CareDx #transplant #transplantcommunity #chimerism #tranplatationwebinar https://lnkd.in/g5Wdr82a
Webinar - Redefining Chimerism Analysis with AlloSeq HCT
start.caredx.com
-
CareDx, Inc.转发了
CareDx Appoints John W. Hanna as its New President and Chief Executive Officer - read more here: https://lnkd.in/g5T_JHUU
-